Catalyst Oncology

Pre-emptive treatment helped curtail skin toxicity with panitumumab (PhysOrg) With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities, according to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

Here is the original: 
Pre-emptive treatment helped curtail skin toxicity with panitumumab (PhysOrg)